How pharma brands handled paid social during Trump’s final 2 weeks in office
Some brands that paused Twitter ads after the Capitol riot have yet to return.
Some brands that paused Twitter ads after the Capitol riot have yet to return.
There were pluses and minuses to attending from afar.
Every crisis has its winners and losers, and this once-in-a-generation pandemic is no exception.
Execs from Pfizer, Sanofi and CVS Health shared company updates with the virtual throng.
Sacrificing equity for vaccine expediency is a bad idea, behavioral-science experts warn.
Eli Lilly drug shows promise in slowing cognitive decline; Japan discovers another COVID strain; Valo Health raises $190 million to develop AI platform.
The annual conference arrives at a moment when pharma’s reputation is riding high for the first time in recent memory.
Arthritis drugs show promise in treating severely ill COVID-19 patients; Scorpion Therapeutics brings in $162 million in funding; UnitedHealth buys Change Healthcare
Biopharma leaders denounce Capitol violence; Senate Democrats likely to push for health policy changes; Wednesday becomes deadliest day in pandemic
MM+M’s most popular pharma stories of the year spanned features the industry’s reaction to the death of George Floyd and COVID-19, surveys on how to navigate challenges due to the pandemic and more.